Filing Flows › Lucid Diagnostics (LUCD) › R&D spending
Lucid Diagnostics (LUCD) R&D spending by quarter
Lucid Diagnostics' R&D spending was $1.2M in Q2 2026 (second quarter 2026), -1% from Q1 2026. Over the last 6 quarters it ranged from $1.2M (Q2 2026) to $1.5M (Q4 2024).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $1.2M | -1% | -5% |
| Q1 2026 | $1.2M | -5% | -16% |
| Q3 2025 | $1.3M | +1% | — |
| Q2 2025 | $1.3M | -12% | — |
| Q1 2025 | $1.4M | -2% | — |
| Q4 2024 | $1.5M | — | — |
Q2 2026 at a glance
Lucid Diagnostics, Q2 2026: revenue $1.5M (+27% year over year), operating margin -868.5%, net loss $11.7M, operating cash flow −$11.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Lucid Diagnostics' R&D spending?
Lucid Diagnostics' R&D spending was $1.2M in Q2 2026 (second quarter 2026), -1% from Q1 2026.
How has Lucid Diagnostics' R&D spending changed?
Over the last 6 quarters it ranged from $1.2M (Q2 2026) to $1.5M (Q4 2024).